^
    1d
    Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum and vivax malaria in Eritrea in 2024 (ACTRN12626000256370)
    P4, N=480, Completed, Ministry of Health
    New P4 trial
    4d
    Co-SAM: An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (clinicaltrials.gov)
    P3, N=674, Active, not recruiting, Queen Mary University of London | Recruiting --> Active, not recruiting | N=1266 --> 674 | Trial primary completion date: Jul 2026 --> Feb 2026
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    rifampicin
    11d
    Mechanical Bowel Preparation With or Without Oral Antibiotics in Left Sided Colorectal Cancer Surgery (clinicaltrials.gov)
    P=N/A, N=60, Enrolling by invitation, Shaukat Khanum Memorial Cancer Hospital & Research Centre
    New trial
    |
    rifampicin
    11d
    Differential gene regulation by SR12813 and rifampicin: Insights into PXR and PPARγ activation and metabolic pathway modulation in LS180 colon cancer cells. (PubMed, Drug Metab Dispos)
    SIGNIFICANCE STATEMENT: SR12813 activates both pregnane X receptor and peroxisome proliferator-activated receptor gamma, demonstrating dual nuclear receptor modulation in colon cancer cells. By linking xenobiotic metabolism with lipid and mitochondrial pathways, this work uncovers previously unreported receptor crosstalk and provides a mechanistic framework for how diverse ligands can differentially shape transcriptional programs relevant to drug metabolism and tumor biology.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • NR1I2 (Nuclear Receptor Subfamily 1 Group I Member 2)
    |
    rifampicin
    18d
    RC24_0404: Rifampin-free regimen versus rifampin-containing regimen in the treatment of staphylococcal prosthetic valve endocarditis: a multicenter randomized controlled non-inferiority study (RIFREE) (2024-518018-22-00)
    P2/3, N=422, Not yet recruiting, Centre Hospitalier Universitaire De Nantes
    New P2/3 trial • Head-to-Head
    |
    rifampicin
    25d
    Shorter and Safer Treatment Regimens for Latent TB (clinicaltrials.gov)
    P2/3, N=1800, Recruiting, McGill University Health Centre/Research Institute of the McGill University Health Centre | Not yet recruiting --> Recruiting
    Enrollment open
    |
    rifampicin
    28d
    Endoglin-targeted cancer therapies: current status and opportunities. (PubMed, Expert Opin Investig Drugs)
    TRC105 (carotuximab), a monoclonal antibody against endoglin, progressed through multiple clinical trials and was well tolerated, yet outcomes were disappointing, revealing a gap between preclinical findings and patient benefit...Future progress requires a deeper mechanistic resolution of endoglin's roles across tumor type and disease stage, along with the development of biomarkers incorporating spatial expression patterns. Successful translation will depend on matching endoglin-targeted therapy to patients and tumor ecosystems most likely to benefit, shifting from broad anti-angiogenic application to precision stromal targeting.
    Journal
    |
    ENG (Endoglin)
    |
    carotuximab IV (ENV-105)
    1m
    The efficacy and complications of rifampin-combined antibiotic therapy for staphylococcal periprosthetic joint infections: A multicenter, randomized controlled trial (ChiCTR2500114844)
    P=N/A, N=428, Not yet recruiting, The First Affiliated Hospital of Fujian Medical University; The First Affiliated Hospital of Fujian Medical University
    New trial
    |
    rifampicin
    1m
    c-Cbl inhibits tumor angiogenesis by promoting METTL3 ubiquitination and pericytes apoptosis in melanoma (ChiCTR2500112645)
    P=N/A, N=136, Not yet recruiting, The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University
    New trial
    1m
    Large extracellular vesicles regulate endothelial angiogenic potential via paracrine and autocrine signaling. (PubMed, J Biol Chem)
    Despite advancements in anti-angiogenic cancer therapies, such as bevacizumab, late-stage tumors, including advanced melanomas, exhibit mixed clinical responses...This L-EV-mediated increase in endothelial tube formation is sensitive to the effects of sorafenib, a multi-kinase inhibitor, but not SU5416, a selective VEGF-receptor inhibitor...Finally, we show that EV subtypes have distinct effects on the acquisition of angiogenic phenotypes and their roles vary with tumor type. These findings provide new insight into the mechanisms of angiogenic therapy resistance in melanoma and demonstrate the differential functions of EV subtypes in angiogenesis across tumor types.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Avastin (bevacizumab) • sorafenib • semaxanib (SU5416)
    1m
    ToxZid: Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis (clinicaltrials.gov)
    P=N/A, N=280, Recruiting, Albert Einstein College of Medicine | Not yet recruiting --> Recruiting | Trial completion date: Sep 2029 --> Dec 2029 | Trial primary completion date: Mar 2029 --> Jun 2029
    Enrollment open • Trial completion date • Trial primary completion date
    |
    rifampicin
    1m
    PORT: Pragmatic Optimized Rifampicin Trial (clinicaltrials.gov)
    P3, N=164, Recruiting, Radboud University Medical Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    rifampicin